Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ:PHAT
PHAT Stock Chart & Stats
$12.41
-$0.22(-3.06%)
At close: 4:00 PM EST
$12.41
-$0.22(-3.06%)
Day’s Range― - ―
52-Week Range$2.21 - $18.31
Previous CloseN/A
Volume285.74K
Average Volume (3M)1.06M
Market Cap
$1.04B
Enterprise Value$835.70M
Total Cash (Recent Filing)$135.16M
Total Debt (Recent Filing)$2.71M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Mar 03, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding78,294,780
10 Day Avg. Volume904,675
30 Day Avg. Volume1,060,214
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-2.02
Price to Sales (P/S)9.28
P/FCF Ratio-1.92
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue5.68
Enterprise Value/Gross Profit6.51
Enterprise Value/Ebitda-4.11
Forecast
1Y Price Target
$25.83Price Target Upside108.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst RevisionsAnalyst updated financial models and modestly raised nearer-term revenue forecasts, indicating stronger anticipated sales growth and reinforcing confidence in the company's near-term outlook.
Commercial AdoptionConsistent growth in filled VOQUEZNA prescriptions and solid launch metrics point to expanding patient adoption and improving market traction for the product.
Cost ManagementSignificant reduction in operating expenses supports management's plan to reach operating profitability in 2026 by extending cash runway and improving margins.
Bears Say
Prescription Fill BarriersConcerns about prescriptions being written but not filled due to insurance coverage gaps and patient follow-up challenges create uncertainty around actual sales conversion and revenue realization.
Revenue Forecast RiskAnalyst lowered a later-period revenue projection, signaling risk that sales growth may decelerate beyond the nearer-term and creating potential downside pressure on the stock.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals, Inc.’s price range in the past 12 months?
Phathom Pharmaceuticals, Inc. lowest stock price was $2.21 and its highest was $18.31 in the past 12 months.
What is Phathom Pharmaceuticals, Inc.’s market cap?
Phathom Pharmaceuticals, Inc.’s market cap is $1.04B.
When is Phathom Pharmaceuticals, Inc.’s upcoming earnings report date?
Phathom Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 25 days.
How were Phathom Pharmaceuticals, Inc.’s earnings last quarter?
Phathom Pharmaceuticals, Inc. released its earnings results on Oct 30, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.463 by $0.053.
Is Phathom Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Phathom Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Phathom Pharmaceuticals, Inc. pay dividends?
Phathom Pharmaceuticals, Inc. does not currently pay dividends.
What is Phathom Pharmaceuticals, Inc.’s EPS estimate?
Phathom Pharmaceuticals, Inc.’s EPS estimate is -0.41.
How many shares outstanding does Phathom Pharmaceuticals, Inc. have?
Phathom Pharmaceuticals, Inc. has 78,294,780 shares outstanding.
What happened to Phathom Pharmaceuticals, Inc.’s price movement after its last earnings report?
Phathom Pharmaceuticals, Inc. reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.463. Following the earnings report the stock price went down -1.626%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PHAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phathom Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.83 (108.14% Upside)
$25.83 (108.14% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 57.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.92%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
PHAT Company Deck
PHAT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Phathom Pharmaceuticals had a strong Q3 with significant revenue growth and a substantial reduction in operating expenses and cash usage. The company is effectively executing its gastroenterology-focused strategy. However, there are potential challenges such as the temporary impact of sales force realignment and ongoing uncertainty in TRIPLE PAK supply.View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
$25.83
▲(108.14% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Urogen Pharma
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
10.91% Insiders
10.35% Mutual Funds
0.21% Other Institutional Investors
70.26% Public Companies and Individual Investors